Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Coronary Artery Disease
About this trial
This is an interventional diagnostic trial for Coronary Artery Disease focused on measuring Regadenoson (Lexiscan), PET N-13 ammonia imaging, Myocardial Blood Flow (MBF), Regadenoson Stress
Eligibility Criteria
Inclusion Criteria:
- Healthy male and female volunteers over the age of 30.
- Written informed consent will be obtained from each subject.
- Each subject will undergo a history and physical examination
Exclusion Criteria:
- Any cardiovascular or pulmonary symptoms or exam findings
- History of low blood pressure (< 90/50 mmHg)
- Prior cardiac history
- History of hypertension
- History of hyperlipidemia
- History of diabetes mellitus
- History of asthma or chronic obstructive pulmonary disease
- Weight of > 450 pounds
- Chronic kidney disease
- Other serious illness such as cancer
- Current smoking
- Medication use (with the exception of acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and thyroid hormone replacement)
- Illicit drug use
- Prior allergic reaction to adenosine, regadenoson, or aminophylline
- Pregnancy
Sites / Locations
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Regadenoson, then Adenosine
Adenosine, then Regadenoson
Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.